부산대학교 도서관

Sir, Although there are no formal guidelines for prophylactic implantable cardioverter defibrillator (ICD) implantation in patients with primary cancer treatment induced arrhythmia, it can be safely undertaken and should be considered on an individual case basis, particularly when continuation with treatment may afford a reasonable quality of life. His electrocardiogram (ECG) whilst on alectinib therapy had shown asymptomatic sinus bradycardia with heart rate around 60 beats per minute (bpm) and consistently normal corrected QT interval (QTc). For patients on treatment with ALK TKIs, such as alectinib, crizotinib, certinib and brigatinib, emphasis is therefore laid upon ECG surveillance, concurrent pharmacological and electrolyte vigilance, and clinicians should be alert to clinical symptoms which may be attributed to ventricular arrhythmias. [Extracted from the article]